Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
1995-02-10
2003-04-22
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S135100, C424S133100, C424S144100, C424S154100, C424S153100, C424S173100, C424S801000, C424S810000, C530S387300, C530S388220, C530S388700, C530S388750, C530S389600, C530S867000, C530S866000, C530S868000, C530S387100
Reexamination Certificate
active
06551593
ABSTRACT:
BACKGROUND OF THE INVENTION
Inflammatory bowel disease (IBD), such as ulcerative colitis and Crohn's disease, for example, can be a debilitating and progressive disease involving inflammation of the gastrointestinal tract affecting an estimated two million people in the United States. Symptoms include abdominal pain, cramping, diarrhea and rectal bleeding. IBD treatments have included anti-inflammatory drugs (such as, corticosteroids and sulfasalazine), immunosuppressive drugs (such as, 6-mercaptopurine, cyclosporine and azathioprine) and surgery (such as, colectomy). Podolsky,
The New England Journal of Medicine,
325:928-937 (1991) and Podolsky,
The New England Journal of Medicine,
325:1008-1016 (1991).
Some studies have suggested that the cell adhesion molecule, ICAM-1, mediates leukocyte recruitment to inflammatory sites through adhesion to leukocyte surface ligands, i.e. Mac-1, LFA-1 or &agr;4&bgr;2 (Springer,
Nature,
346:425-434 (1990)). In addition, vascular cell adhesion molecule-1 (VCAM-1), recognizing the &agr;4&bgr;1 integrin (VLA-4), has been reported to play a role in in vivo leukocyte recruitment as well (Silber et al.,
J. Clin. Invest.
93:1554-1563 (1994)). It has been proposed that IBD can be treated by blocking the interaction of ICAM-1 with LFA-1 or Mac-1 or VCAM-1 with &agr;4&bgr;1 (e.g., WO 93/15764). However, these therapeutic targets are likely involved in inflammatory processes in multiple organs, and a functional blockade would likely result in systemic immune dysfunction.
Mucosal addressin MAdCAM, a mucosal vascular adhesion molecule, is a 58-66K glycoprotein adhesion receptor for lymphocytes which is distinct from VCAM-1 and ICAM-1 (Briskin et al.,
Nature,
363:461-463 (1993)). In contrast to VCAM-1 and ICAM-1, MAdCAM is preferentially expressed in the gastrointestinal tract, binds the &agr;4&bgr;7 integrin (also called LPAM-1 and CD49d/CD
−
) found on lymphocytes, and participates in the homing of these cells to mucosal sites, such as Peyer's patches in the intestinal wall (Hamann et al.,
Journal of Immunology,
152:3282-3293 (1994)). The use of inhibitors to the binding of MAdCAM to the receptor, &agr;4&bgr;7, in the treatment of diseases such as IBD has not been suggested.
SUMMARY OF THE INVENTION
The invention relates to the treatment of individuals suffering from a disease associated with leukocyte recruitment to the gastrointestinal tract as a result of binding of leukocytes to gut-associated endothelium expressing the molecule MAdCAM, comprising administering to the individual an effective amount of a compound, such as an antibody, which inhibits the binding of leukocytes to endothelial MAdCAM. The antibody is preferably monoclonal, chimeric and/or humanized or an antigen binding fragment thereof, and inhibits adhesion of leukocytes expressing an integrin containing the &bgr;7 chain (such as &agr;4&bgr;7) to endothelium expressing MAdCAM. In one embodiment, the monoclonal antibody or antigen binding fragment thereof has the antigenic specificity of a monoclonal antibody selected from the group consisting of FIB 21, FIB 30, FIB 504 and ACT-1. Inflammatory bowel diseases, such as but not limited to ulcerative colitis, Crohn's disease, Pouchitis, celiac disease, microscopic or collagenous colitis, and eosinophilic gastroenteritis can be treated according to the claimed method.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5225539 (1993-07-01), Winter
patent: 5403919 (1995-04-01), Butcher
patent: 5530101 (1996-06-01), Queen et al.
patent: 5538724 (1996-07-01), Butcher et al.
patent: 5558864 (1996-09-01), Bendig et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5594120 (1997-01-01), Brenner et al.
patent: 5599676 (1997-02-01), Vonderheide et al.
patent: 5610281 (1997-03-01), Brenner et al.
patent: 5730978 (1998-03-01), Wayner
patent: 5840299 (1998-11-01), Bendig et al.
patent: 5932214 (1999-08-01), Lobb et al.
patent: 0 303 463 (1994-11-01), None
patent: 6303990 (1994-11-01), None
patent: 90/07321 (1990-07-01), None
patent: 91/09967 (1991-07-01), None
patent: 93/02191 (1993-02-01), None
patent: 93/15764 (1993-08-01), None
patent: 93/23526 (1993-11-01), None
patent: 94/13312 (1994-06-01), None
patent: 94/16094 (1994-07-01), None
patent: 94/17828 (1994-08-01), None
patent: 95/19790 (1995-07-01), None
patent: 97/18838 (1997-05-01), None
Sela, “Overview: antigens” from “Handbook of Exp. Immunol., Immunochemistry” ed. Weir et al., Balckwell Sci. Pub., 1986, pp. 1.1-1.7.*
Podolsky et al., J. Clin. Invest., 92:372-380, 1993.*
Berlin et al., Cell, 74: 185-195, 1993.*
Osband et al., Imm Today, 11: 103-105, 1990.*
Harris et al., TIBTECH, 11:42-44, 1993.*
Waldmann, Science, 252: 1657-1662, 1991.*
Tidswell, M., et al., “Structure-Function Analysis of the Integrin &bgr;7Subunit,”J. Immunol., 159:1497-1505 (1997).
Pulido, R., et al., “Functional Evidence for Three Distinct and Independently Inhibitable Adhesion Activities Mediated by the Human Integrin VLA-4,”J. Biol. Chem., 266(16):10241-10245 (1991).
Sánchez-Madrid, F., et al., “VLA-3: A Novel Polypeptide Association Within the VLA Molecular Complex: Cell Distribution and Biochemical Characterization,”Eur. J. Immunol., 16:1343-1349, (1986).
Ringler, D.J. et al., “Cellular Localization of Simian Immuno-deficiency Virus in Lymphoid Tissues I. Immunohistochemistry and Electron Microscopy,”American Journal of Pathology134(2):373-383 (1989).
Strober, Warren and Ehrhardt, Rolf O., “Chronic Intestinal Inflammation: An Unexpected Outcome in Cytokine or T Cell Receptor Mutant Mice,”Cell75:203-205 (1993).
Sadlack, Benjamin et al., “Ulcerative Colitis-like Disease in Mice with a Disrupted Interleukin-2 Gene,”Cell75:253-261 (1993).
Hamann, Alf et al., “Role of &agr;4-Integrins in Lymphocyte Homing to Mucosal Tissues In Vivo,”Journal of Immunology152:3282-3293 (1994).
Cooper, Harry S. et al., “Clinicopathologic Study of Dextran Sulfate Sodium Experimental Murine Colitis,”Laboratory Investigation69(2):238-249 (1993).
Okayasu, Isao et al., “Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice,”Gastroenterology98:694-702 (1990).
Podolsky, Daniel K., “Inflammatory Bowel Disease (First of Two Parts),”The New England Journal of Medicine325 (13):928-937 (1991).
Podolsky, Daniel K., “Inflammatory Bowel Disease (Second of Two Parts),”The New England Journal of Medicine325 (14):1008-1016 (1991).
Springer, Timothy A., “The Sensation and Regulation of Interactions with the Extracellular Environment: The Cell Biology of Lymphoctye Adhesion Receptors,”Ammu. Rev. Cell Biol.6:359-402 (1990).
Dueñas, Marta and Borrebaeck, Carl A.K., “Clonal Selection and Amplification of Phage Displayed Antibodies by Linking Antigen Recognition and Phage Replication,”Bio/Technology12:999-1002 (1994).
Picker, Louis, J. and Butcher, Eugene C., “Physiological and Molecular Mechanisms of Lymphocyte Homing,”Annu. Rev. Immunol.10:561-591 (1992).
Hynes, Richard O., “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion,”Cell69:11-25 (1992).
Michie, Sara A. et al., “The Human Peripheral Lymph Node Vascular Addressin, An Inducible Endothelial Antigen Involved in Lymphocyte Homing,”American Journal of Pathology143(6):1688-1698 (1993).
Schweighoffer, Tamas et al., “Selective Expression of Integrin &agr;4&bgr;7 on a Subset of Human CD4+Memory T Cells with Hallmarks of Gut-Trophism,”The Journal of Immunology151(2):717-729 (1993).
Springer, Timothy A. “Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm,”Cell76:301-314 (1994).
Briskin, Michael J. et al., “MadCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1,”Nature363:461-463 (1993).
Salmi, Marko et al., “Aberrant Binding of Lamina Propria Lymphocytes to Vascular Endothelium in Inflammatory Bowel Diseases,”Gastroenterology106:596-605 (1994).
Silber, Alexandra et al., “Recruitment of Lymphocytes during Cutaneous Delayed Hypersensitivity in Nonhuman Primates is Dependent on E-Selectin and Vascular Cell Adhesion Molecule 1,”J.
Newman Walter
Picarella Dominic
Ringler Douglas J.
Hamilton Brook Smith & Reynolds P.C.
Millennium Pharmaceuticals Inc.
Schwadron Ronald B.
LandOfFree
Treatment of Inflammatory bowel disease by inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of Inflammatory bowel disease by inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of Inflammatory bowel disease by inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3091860